PEG-rhGH

Phase 2Small molecule

Changchun GeneScience Pharmaceutical Co., Ltd.

PEG-rhGH is one of 23 small molecule programs targeting Small for gestational age. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small for Gestational AgeActive, not recruiting

Short StatureActive, not recruiting

Small for Gestational AgePhase 2

Active, not recruiting

Short StaturePreclinical

Active, not recruiting

Competition

Competitive Landscape

28 competitors in Short Stature

#DrugCompanyPhaseTrials

Growth Hormone

Pfizer

Phase 3

2 2

Aromatase Inhibitor

Pfizer

Phase 3

1 3

Genotropin

Pfizer

Phase 3

1 4

Saizen

Merck & Co.

Phase 3

1 5

Leuprorelin

Takeda

Phase 3

1 6

Voxzogo

BioMarin Pharmaceutical

Phase 2

2 7

Genotropin

EMD Serono

Phase 2

4 8

GH Treatment (genotropin)

RRabin Medical Center

Approved

1 9

Rhgh

XXiamen Amoytop Biotech Co., Ltd.

Phase 2

1 10

Increlex

EEsteve Pharmaceuticals, S.A.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Small for Gestational Age

NCT07260500

N/ANot yet recruiting

Short Stature

NCT06768411

Clinical

Trials by Indication[1]

Cognitive Development1 trial

A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants

Recruiting·TTongji Hospital·Phase 4·NCT05144035·138 enrolled

Small for gestational age1 trial

A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT07260500·72 enrolled

Short stature1 trial

The Dosage Exploration Study of PEG-rhGH for Treating Short Stature in Prepubertal and Pubertal Children

Not yet recruiting·SSecond Affiliated Hospital of Wenzhou Medical University·N/A·NCT06768411·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PEG-rhGH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG-rhGH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG-rhGH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changchun GeneScience Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Changchun GeneScience Pharmaceutical Co., Ltd.

PEG-rhGH

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cognitive Development1 trial

Small for gestational age1 trial

Short stature1 trial

References

Drug Info

Quick Facts

Related News